Skip to main content
AmigoFish

Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly

From Pharmaceutical Executive · · 3 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.

Back to Pharmaceutical Executive · Report a problem